Evidence map›Paper›PMID 36284643›Full record

ArticleEuropean heart journal open2022

Achievements of primary prevention targets in individuals with high risk of cardiovascular disease: an 8-year follow-up of the Tromsø study.

Amalie Nilsen Hagen, Inger Ariansen, Tove Aminda Hanssen, Knut Tore Lappegård, Anne Elise Eggen, Maja-Lisa Løchen, Inger Njølstad, Tom Wilsgaard, Laila Arnesdatter Hopstock

Open access · goldAbstract read
In one paragraph

Article in European heart journal open, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.1field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Highlights from 2022 inEuropean heart journal open · 2022
    Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Amalie Nilsen HagenDepartment of Medicine, Nordland Hospital, Parkveien 96, Nordland, 8005 Bodø, Norway.ORCID https://orcid.org/0000-0002-7462-4778
Inger AriansenDepartment of Chronic Diseases and Ageing, Norwegian Institute of Public Health, Folkehelseinstituttet, Postboks 222 Skøyen, 0213 Oslo, Norway.ORCID https://orcid.org/0000-0001-8529-4826
Tove Aminda HanssenDepartment of Cardiology, University Hospital of North Norway, Universitetssykehuset Nord-Norge HF Postboks 100, 9038 Tromsø, Norway.
Knut Tore LappegårdDepartment of Medicine, Nordland Hospital, Parkveien 96, Nordland, 8005 Bodø, Norway.
Anne Elise EggenDepartment of Community Medicine, UiT The Arctic University of Norway, UiT Noregs arktiske universitet Postboks 6050 Langnes, 9037 Tromsø, Norway.
Maja-Lisa LøchenDepartment of Cardiology, University Hospital of North Norway, Universitetssykehuset Nord-Norge HF Postboks 100, 9038 Tromsø, Norway.ORCID https://orcid.org/0000-0002-8532-6573
Inger NjølstadDepartment of Community Medicine, UiT The Arctic University of Norway, UiT Noregs arktiske universitet Postboks 6050 Langnes, 9037 Tromsø, Norway.ORCID https://orcid.org/0000-0002-6391-231X
Tom WilsgaardDepartment of Community Medicine, UiT The Arctic University of Norway, UiT Noregs arktiske universitet Postboks 6050 Langnes, 9037 Tromsø, Norway.
Laila Arnesdatter HopstockDepartment of Community Medicine, UiT The Arctic University of Norway, UiT Noregs arktiske universitet Postboks 6050 Langnes, 9037 Tromsø, Norway.ORCID https://orcid.org/0000-0003-0072-7421
UiT The Arctic University of Norway · NONordland Hospital · NOUniversity Hospital of North Norway · NONorwegian Institute of Public Health · NO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Aims: To study change over 8 years in cardiovascular risk, achievement of national guideline-based treatment targets of lipids, blood pressure (BP) and smoking in primary prevention of cardiovascular disease (CVD), medication use, and characteristics associated with target achievement among individuals with high CVD risk in a general population. Methods and results: We followed 2524 women and men aged 40-79 years with high risk of CVD attending the population-based Tromsø study in 2007-08 (Tromsø6) to their participation in the next survey in 2015-16 (Tromsø7). We used descriptive statistics and regression models to study change in CVD risk and medication use, and characteristics associated with treatment target achievement. In total, 71.4% reported use of BP- and/or lipid-lowering medication at second screening. Overall, CVD risk decreased during follow-up, with a larger decrease among medication users compared with non-users. Treatment target achievement was 31.0% for total cholesterol <5 mmol/L, 27.3% for LDL cholesterol <3 mmol/L, 43.4% for BP <140/90 (<135/85 if diabetes) mmHg, and 85.4% for non-smoking. A total of 9.8% reached all treatment targets combined. Baseline risk factor levels and current medication use had the strongest associations with treatment target achievement. Conclusion: We found an overall improvement in CVD risk factors among high-risk individuals over 8 years. However, guideline-based treatment target achievement was relatively low for all risk factors except smoking. Medication use was the strongest characteristic associated with achieving treatment targets. This study has demonstrated that primary prevention of CVD continues to remain a major challenge.

Indexed as

AntihypertensivesCardiovascular diseaseCohort studiesLipid-lowering drugsPrimary prevention

Identifiers

PMID36284643
PMCPMC9583183
OpenAlexW4296691006

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.